Research Paper Volume 15, Issue 21 pp 12651—12673
Discovery and identification of the prognostic significance and potential mechanism of FMO2 in breast cancer
Figure 2. Relationship between FMO2 and different clinical indicators in TCGA. (A) Nature of the tissue. (B) ER status. (C) PR status. (D) ER and PR status combinations. (E) HER2 status. (F) Histological types. (G) Pathological tumor stage. (H) Age status. (I) PAM50 subtypes. (J) Basal-like (PAM50). (K) Triple-negative breast cancer. (L) Basal-like (PAM50) and triple-negative breast cancer.